1. Centro de Coordinación de Alertas y Emergencias Sanitarias. Ministerio de Sanidad [consultado 24 Feb 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_282_COVID-19.pdf
2. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab Rituximab, and Injectable Therapies;Luna;JAMA Neurol,2020
3. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study. Eur Respir J. 2020;55:2000524. DOI 10.1183/13993003.00524-2020. Erratum in: Eur Respir J. 2020;56:32269088.
4. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic;Baker;Mult Scler Relat Disord,2020
5. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases;Möhn;J Clin Med,2020